Thursday, February 03, 2022 7:27:26 PM
Thank you for the information. Trying to increase my optimism!
Recent ATNM News
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting • PR Newswire (US) • 04/06/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:39:32 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/26/2026 09:00:06 PM
- Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting • PR Newswire (US) • 02/17/2026 12:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 10:00:30 PM
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer • PR Newswire (US) • 12/12/2025 01:45:00 PM
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium • PR Newswire (US) • 12/01/2025 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 10:00:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:50:40 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/05/2025 10:03:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/05/2025 10:02:26 PM
- Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications • PR Newswire (US) • 11/04/2025 12:30:00 PM
- Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference • PR Newswire (US) • 11/03/2025 01:30:00 PM
- Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecu • PR Newswire (US) • 10/27/2025 11:00:00 AM
- Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat • PR Newswire (US) • 10/24/2025 12:30:00 PM
- Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 10/13/2025 04:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2025 09:00:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2025 09:00:44 PM
- Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combi • PR Newswire (US) • 07/31/2025 12:30:00 PM
- Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molec • PR Newswire (US) • 06/23/2025 03:30:00 PM
- Life Sciences Investor Forum: Now Available for Online Viewing • GlobeNewswire Inc. • 06/13/2025 12:35:00 PM
- Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 06/10/2025 03:36:00 PM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM • PR Newswire (US) • 05/22/2025 09:45:00 AM
- Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) • PR Newswire (US) • 05/19/2025 05:04:00 PM
